Patent · US Active

Aflibercept formulations and uses thereof

US11135266B2 · kind B2 · utility

3Cited by
29References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 20, 2017
Grant dateOct 5, 2021
Priority date
Expiry dateJan 17, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P27/02
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.